Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Daily Top 10 COVID-19 publications

Deutsch | English | Español | Français | Italiano | Português; | Tiếng Việt | Türkçe

  Malignant Lymphoma

  Free Subscription


1 Am J Hematol
1 Blood
1 BMC Cancer
1 Bone Marrow Transplant
3 Br J Haematol
2 Cancer
1 Haematologica
1 Int J Radiat Oncol Biol Phys
1 J Clin Oncol
4 Leuk Lymphoma
1 Leukemia
1 PLoS One
1 Radiother Oncol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Hematol

  1. QI SN, Yang Y, Zhang YJ, Huang HQ, et al
    Risk-based, Response-adapted Therapy for Early-stage Extranodal Nasal-type NK/T-cell Lymphoma in the Modern Chemotherapy Era: A China Lymphoma Collaborative Group (CLCG) Study.
    Am J Hematol. 2020 May 25. doi: 10.1002/ajh.25878.
    PubMed         Abstract available


  2. DE BOER M, Hauptmann M, Hijmering NJ, van Noesel CJM, et al
    Increased prevalence of BRCA1/2 mutations in women with macro-textured breast implants and anaplastic large cell lymphoma of the breast.
    Blood. 2020 May 26. pii: 457298. doi: 10.1182/blood.2019004498.

    BMC Cancer

  3. EL YACOUBI H, Sow ML, Kettani F, Gamra L, et al
    Frequency of anaplastic lymphoma kinase rearrangements in Moroccan patients with non small cell lung cancer: a multi-institutional national retrospective study.
    BMC Cancer. 2020;20:479.
    PubMed         Abstract available

    Bone Marrow Transplant

  4. SELLNER L, Schetelig J, Koster L, Choi G, et al
    Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey.
    Bone Marrow Transplant. 2020 May 22. pii: 10.1038/s41409-020-0946.

    Br J Haematol

  5. KOHORST MA, Nunez CA, Tewari P, Petropoulos D, et al
    Primary mediastinal large B-cell lymphoma in paediatric and adolescent patients: emerging questions in the era of immunotherapy.
    Br J Haematol. 2020 May 29. doi: 10.1111/bjh.16761.

  6. LAUER EM, Waterhouse M, Braig M, Mutter J, et al
    Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.
    Br J Haematol. 2020 May 26. doi: 10.1111/bjh.16759.

  7. TUCKER D, Morley N, MacLean P, Vandenberghe E, et al
    The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma.
    Br J Haematol. 2020 May 23. doi: 10.1111/bjh.16739.
    PubMed         Abstract available


  8. LEE MJ, Koff JL, Switchenko JM, Jhaney CI, et al
    Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-Cell lymphoma.
    Cancer. 2020 May 29. doi: 10.1002/cncr.32866.
    PubMed         Abstract available

  9. EPPERLA N, Hamadani M, Reljic T, Kharfan-Dabaja MA, et al
    Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis.
    Cancer. 2019 Aug 23. doi: 10.1002/cncr.32464.
    PubMed         Abstract available


  10. TABANELLI V, Melle F, Motta G, Mazzara S, et al
    Evolutionary crossroads: morphological heterogeneity reflects divergent intra-clonal evolution in a case of high-grade B-cell lymphoma.
    Haematologica. 2020 May 28. pii: haematol.2020.249664.

    Int J Radiat Oncol Biol Phys

  11. WRIGHT CM, LaRiviere MJ, Baron JA, Uche C, et al
    Bridging Radiation Therapy Prior to Commercial Chimeric Antigen Receptor T-Cell Therapy for relapsed/refractory aggressive B-cell lymphoma.
    Int J Radiat Oncol Biol Phys. 2020 May 21. pii: S0360-3016(20)31138.
    PubMed         Abstract available

    J Clin Oncol

  12. ROSCHEWSKI M, Dunleavy K, Abramson JS, Powell BL, et al
    Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.
    J Clin Oncol. 2020 May 26:JCO2000303. doi: 10.1200/JCO.20.00303.
    PubMed         Abstract available

    Leuk Lymphoma

  13. HA CS, LeBlanc M, Schoder H, Pinnix CC, et al
    Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816.
    Leuk Lymphoma. 2020 May 26:1-6. doi: 10.1080/10428194.2020.1768388.
    PubMed         Abstract available

  14. ASKLID A, Eketorp Sylvan S, Mattsson A, Winqvist M, et al
    A real-world study of first-line therapy in 280 consecutive Swedish patients >/=80 years with newly diagnosed diffuse large B-cell lymphoma: very elderly (>/=85 years) do well on curative intended therapy.
    Leuk Lymphoma. 2020 May 25:1-9. doi: 10.1080/10428194.2020.1765233.
    PubMed         Abstract available

  15. AGUILAR C, Laberiano C, Beltran B, Diaz C, et al
    Clinicopathologic characteristics and survival of patients with primary effusion lymphoma.
    Leuk Lymphoma. 2020 May 25:1-10. doi: 10.1080/10428194.2020.1762881.
    PubMed         Abstract available

  16. YANG R, Huo Z, Duan Y, Tong W, et al
    SOX11 inhibits tumor proliferation and promotes cell adhesion mediated-drug resistance via a CD43 dependent manner in mantle cell lymphoma.
    Leuk Lymphoma. 2020 May 23:1-14. doi: 10.1080/10428194.2020.1762877.
    PubMed         Abstract available


  17. DRIESSEN J, Visser O, Zijlstra JM, Lugtenburg PJ, et al
    Primary therapy and relative survival in classical Hodgkin lymphoma: a nationwide population-based study in the Netherlands, 1989-2017.
    Leukemia. 2020 May 28. pii: 10.1038/s41375-020-0875.
    PubMed         Abstract available

    PLoS One

  18. MONRAD I, Madsen C, Lauridsen KL, Honore B, et al
    Glycolytic biomarkers predict transformation in patients with follicular lymphoma.
    PLoS One. 2020;15:e0233449.
    PubMed         Abstract available

    Radiother Oncol

  19. DURHAM AD, Lovis A, Simons J, Long O, et al
    Percussion assisted radiation therapy in Hodgkin lymphoma allows a marked reduction in heart dose.
    Radiother Oncol. 2020 May 21. pii: S0167-8140(19)33475.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.